Condition: Diabetes Mellitus · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2 · Sponsor: Senseonics, Inc.
A prospective, multicenter evaluation of performance and safety of the Eversense Gemini System with flash glucose measurement feature. The purpose of this clinical investigation is to evaluate the accuracy of the Gemini System with new technological flash glucose monitoring (FGM) feature enhancements compared to reference glucose measurements and the Eversense 365 CGM System. The investigation will also evaluate safety of the Gemini System usage.
This description comes directly from the study's public registry record.
Maggie Lewis · 667-218-3309 · maggie.lewis@senseonics.com
Susan Huynh · 301-407-2923 · susan.huynh@senseonics.com
Always discuss trial participation with your own doctor first.
| Headlands Research - AMCR Institute | Escondido, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07386340